Epigenetic Mapping in Pancreatic Cells Identifies New Diabetes Target

Researchers at Lund University in Sweden have conducted the first study looking at epigenetic changes associated with type 2 diabetes in alpha and beta pancreatic cells. Published today in Nature Metabolism, their findings show that the ONECUT2 gene plays a key role in the development of type 2 diabetes by altering insulin production. 

“The study shows that many genes central to insulin and glucagon production are regulated by differences in DNA methylation,” says Charlotte Ling, PhD, professor of epigenetics at Lund University and lead author of the study. “It has made it possible, for the first time, to describe detailed, cell-specific epigenetic patterns.”

The number of people living with diabetes is rapidly increasing worldwide, with approximately 95% of cases attributed to type 2 diabetes. This condition develops gradually and is characterized by a reduced ability to use insulin effectively, leading to elevated blood sugar levels. Over time, high blood sugar can lead to a range of complications that significantly impact the patient’s quality of life. 

Lifestyle factors like diet and physical activity are major drivers of this condition; however, genetics can also contribute to the development of type 2 diabetes, increasing the risk for some people over others. While genome- and epigenome-wide studies on diabetes have identified genetic and epigenetic mechanisms involved in type 2 diabetes, previous epigenetics studies had only looked at whole tissues and none had investigated epigenetic changes within specific cell types that are involved in blood sugar regulation. 

Ling’s team focused on alpha and beta pancreatic cells, which secrete insulin and glucagon hormones, respectively, to regulate blood sugar levels. By analyzing hundreds of thousands of cells from 24 people, with and without diabetes, the researchers created the most detailed epigenetics mapping of pancreatic cells to date. This allowed them to discover over 22,000 regions in nearly 8,000 genes that were differentially methylated between alpha and beta cells. 

“Here, for the first time, we show exactly which regions regulate insulin and glucagon production through DNA methylation, which gives us the opportunity to develop future treatments based on epigenetics,” says Ling.    

They then used CRISPR epigenetic editing to alter DNA methylation around the genes encoding for insulin and glucagon, which revealed that levels of the ONECUT2 transcription factor were elevated in beta cells from type 2 diabetes patients. This epigenetic upregulation was found to impair the ability of beta cells to release insulin, which in turn disrupted glucose regulation and reduced energy production within the cell.

Based on their findings, the researchers developed a web tool intended as a comprehensive resource available to researchers investigating the impact of age, sex, and type 2 diabetes on DNA methylation and gene expression in alpha and beta cells. 

“We now want to understand which of these changes can actually be reversed, and whether this can help beta cells regain their function in diabetes,” says Ling. “A key aspect is to see whether the effects of editing DNA methylation can be sustained in the cell over time.” 

The post Epigenetic Mapping in Pancreatic Cells Identifies New Diabetes Target appeared first on Inside Precision Medicine.

STAT+: FDA to speed up review of three psychedelics as mental health treatments

The Food and Drug Administration will accelerate its review of psychedelic drugs developed by Compass Pathways, the Usona Institute, and Transcend Therapeutics for mental health disorders, as part of the Trump administration’s plan to boost access to the controversial yet promising medications.

The agency will grant priority review vouchers specifically to Compass’ psilocybin product for treatment-resistant depression, Usona’s similar medicine for major depressive disorder, and an MDMA-like treatment for post-traumatic stress disorder from Transcend. 

The FDA identified the medications receiving the vouchers, but not the companies developing them. Compass, Usona, and Transcend confirmed they received vouchers.

Continue to STAT+ to read the full story…

Fibroblast Subset Directs Immune Cell Positioning in Lymph Nodes

Researchers at the University of Lausanne have identified a specialized fibroblast population that actively organizes immune cell interactions within lymph nodes, revealing a key mechanism underlying effective T cell responses to infection and cancer.

The study, published in Immunity, shows that stromal cells, long considered primarily structural, play a central role in orchestrating where and how immune cells meet, with direct consequences for immune activation and memory formation.

Spatial organization drives immune efficiency

Lymph nodes act as surveillance hubs of the immune system, filtering lymphatic fluid and coordinating responses to pathogens or tumor cells. Within these small, highly organized structures, immune cells are not randomly distributed. Instead, they occupy defined niches that facilitate efficient communication.

Cytotoxic T lymphocytes (CTLs), for example, are typically positioned in central regions of the lymph node, where they interact with type 1 dendritic cells (cDC1s) that present antigen and initiate activation. As explained by the study authors, “cytotoxic T lymphocytes are typically found in central regions of the lymph node, where they colocalize and interact with specialized cells called type 1 dendritic cells that present danger signals to them.”

While the importance of this organization has long been appreciated, the mechanisms guiding immune cells to the correct locations have remained incompletely understood.

A fibroblast niche organizes T cell positioning

To address this question, the Lausanne team focused on fibroblasts, a class of stromal cells that form the structural backbone of lymphoid tissues. Using mouse models and human lymph node samples, they identified a distinct subset of fibroblasts located in the central compartment.

These fibroblasts are characterized by expression of MAdCAM1 and by their production of high levels of the chemokine CCL19. This signaling molecule acts as an attractant that guides cytotoxic T cells into proximity with dendritic cells, enabling productive immune interactions. As the researchers note, CCL19 “acts as an ‘attractant signal’ for cytotoxic T lymphocytes, bringing them into physical contact with type 1 dendritic cells.”

By shaping this spatial organization, the fibroblast subset creates a functional niche that promotes T cell activation. When this system was disrupted, cytotoxic T cells failed to position correctly and showed impaired differentiation into memory T cells, highlighting the importance of tissue architecture for long-term immunity.

Notch signaling maintains the stromal network

The researchers also identified the molecular pathway that sustains this fibroblast population. A signaling axis involving Notch2 and its downstream mediator RBPj was found to be essential for maintaining the identity and activity of the CCL19-producing fibroblasts.

In addition, Jagged-1, a ligand produced primarily by dendritic cells, appears to initiate or reinforce this signaling loop. This suggests a feedback mechanism in which immune cells and stromal cells cooperate to maintain the lymph node architecture.

According to the scientists, this pathway must remain active throughout life. When Notch2 signaling was disrupted in fibroblasts, the structural integrity of the niche was lost, leading to defective T cell responses and reduced formation of memory cells.

A conserved mechanism across immune tissues

Although the study focused on lymph nodes, the same organizational principles appear to extend to other immune organs. The researchers observed similar regulation of CCL19 production in the spleen and Peyer’s patches, which are involved in blood filtration and intestinal immunity.

Comparable fibroblast populations were also identified in human lymph nodes, suggesting that this mechanism is conserved across species and relevant to human immune function.

Implications for immunotherapy and vaccines

The findings add to a growing body of evidence that stromal cells play active roles in shaping immune responses. Rather than acting as passive scaffolds, fibroblasts help define where immune interactions occur and how effectively they proceed.

This has important implications for disease. In cancer, for example, ineffective T cell responses may result not only from intrinsic immune dysfunction but also from disrupted tissue organization that prevents optimal cell–cell interactions.

In vaccination, enhancing the formation or function of such stromal niches could improve immune activation and the development of long-lasting memory responses.

Looking ahead

The identification of a fibroblast-driven mechanism for organizing immune cell positioning provides a new foundation for understanding how immune responses are initiated and maintained.

Future research will be needed to explore whether targeting stromal signaling pathways, such as Notch2, can be used to modulate immune responses in therapeutic settings. While such approaches remain speculative, they highlight the potential of integrating tissue architecture into the design of next-generation immunotherapies.

“Overall, these findings deepen our understanding of the organization of the immune system and how effective T cell responses against infections and cancer are initiated,” said Sanjiv Luther, PhD, senior author of the study. “In the future, this knowledge could help improve vaccine design and clarify why immune defenses sometimes fail against certain pathogens or tumors.”

The post Fibroblast Subset Directs Immune Cell Positioning in Lymph Nodes appeared first on Inside Precision Medicine.

STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B

Kelonia Therapeutics became the newest biotech takeout target this week. The privately held company, which is developing cell therapies for cancer and autoimmune diseases, will be acquired by Eli Lilly. 

The acquisition is a boon for the small startup, which has subsisted on $60 million over the last five years and previously struggled to stay afloat. (Check out an earlier slide deck and memo on the company here.) Kelonia came within a week of running out of cash three times. Now it’s being bought for $3.2 billion with potential milestone payments that could double that payout.

On this week’s edition of its biotech podcast, “The Readout Loud,” STAT spoke with Bryan Roberts, a partner at VC firm Venrock, which incubated the biotech, to discuss how this small company managed to land a big deal. 

Continue to STAT+ to read the full story…

STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment

Utah’s high-profile experiment with using an artificial intelligence system to renew prescriptions without physician oversight is facing its first major challenge as doctors in the state push back.

Utah’s Office of Artificial Intelligence Policy in January announced an agreement with AI doctor startup Doctronic to launch a chatbot that can conduct a clinical evaluation of a patient and autonomously renew prescriptions for nearly 200 drugs. In a letter published Friday, the Utah Medical Licensing Board said it only learned about the agreement after it had been launched and asked the state to halt the program.

“Proceeding with this agreement without consulting the Medical Board potentially places Utah citizens at risk and remains a major concern of the board,” they wrote. “It is the strong recommendation of the Utah Medical Licensing Board that this program be immediately suspended pending further discussion.”

Continue to STAT+ to read the full story…

<![CDATA[Definium’s CMO says FDA talks stay aligned with their plans for advancing DT120 ODT for the treatment of depression, anxiety, and now PTSD.]]>

AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains

Some GEN editors were in sunny San Diego covering the hottest research, trends, and products from the American Association for Cancer Research meeting. We kick things off with news from America’s Finest City, particularly around the growing role of AI in oncology. Then we dive into two new research studies. In the first, scientists used CRISPR to identify genes in primary CD4+ T cells that promote or restrict HIV infection. The second study described engineered implantable liver constructs that could eventually serve as a stopgap for patients waiting for donor transplants. Finally, the acquisitions keep coming as Eli Lilly scoops up CAR T cell therapy developer Kelonia for $7B. Also, Revolution Medicines has shared some impressive data from a Phase III trial of its pancreatic cancer drug.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

AACR 2026: A Video Update from San Diego
By Julianna LeMieux, PhD, and Damian Doherty, GEN, April 21, 2026

AACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven Era
By Fay Lin, PhD, and Jonathan Grinstein, PhD, GEN, April 22, 2026

Using AI in Healthcare Ethically by Considering Humanity
By Corinna Singleman, PhD, IPM, November 18, 2025

10x Genomics Unveils Atera Spatial Platform at AACR Meeting
By Julianna LeMieux, PhD, GEN, April 19, 2026

CRISPR Screens Map Human T‑Cell Genes That Promote or Block HIV Infection
GEN, April 20, 2026

Synthetic Biology and Tissue Engineering Grow Liver Tissue In‑Body
GEN, April 20, 2026

StockWatch: Revolution’s Phase III Pancreatic Cancer Data Dazzles Investors, Analysts
By Alex Philippidis, GEN Edge, April 19, 2026

Lilly to Acquire Kelonia for Up to $7B, Expanding Cancer Cell Therapy Pipeline
By Alex Philippidis, GEN Edge, April 20, 2026

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD

The post AI in Oncology Takes Off, Tackling HIV and Liver Disease, Pharma’s Recent Gains appeared first on GEN – Genetic Engineering and Biotechnology News.

<![CDATA[In this CME article, learn how depression hides in organ failure, transplants, neurologic disease, and hormonal shifts—plus screening tips and safer treatment choices.]]>
<![CDATA[Explore GLP-1 agonists and their “truly transformative” role in psychiatry in this podcast. ]]>